Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31188292 | 0.88 | ALDH1A1 (0.49) | ALDH1A1GAAHTR4MAPTTSHR | |
| SCHEMBL16423703 | 0.83 | CYP1A2 (0.48) | ALDH1A1GAAMAPTTSHRKDM4E | |
| SCHEMBL16423275 | 0.83 | ALDH1A1 (0.43) | ALDH1A1GAANR1H4CYP1A2CYP2D6 | |
| SCHEMBL224165 | 0.83 | ALDH1A1 (0.71) | ALDH1A1GAAHTR4MAPTTSHR | |
| SCHEMBL14859534 | 0.82 | ACHE (0.46) | ALDH1A1MAPTHTTACHEKDM4E | |
| Hydrochloric Acid SCHEMBL7410231 | 0.81 | ALDH1A1 (0.69) | ALDH1A1GAAHTR4MAPTTSHR | |
| SCHEMBL22091991 | 0.81 | GABRG2 (0.42) | ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL25942077 | 0.81 | GPR27 (0.41) | ALDH1A1GAAMAPTKDM4ECYP1A2 | |
| SCHEMBL28627930 | 0.81 | GAA (0.58) | ALDH1A1GAAMAPTTSHRMAPK1 | |
| SCHEMBL27947728 | 0.81 | KDM4E (0.44) | ALDH1A1GAAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725944-A1 | NEW METHOD FOR PREPARING OXOPYRIDINE COMPOUND, AND KEY INTERMEDIATE AND USE | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| CN-116262736-B | Novel oxo-pyridine compound and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-115066417-B | Factor XIa inhibitors | 上海京新生物医药有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2024251276-A1 | NEW METHOD FOR PREPARING OXOPYRIDINE COMPOUND, AND KEY INTERMEDIATE AND USE | 成都施贝康生物医药科技有限公司 | 2024-12-12 | — | — | WO | disclosed |
| CN-116874387-A | Novel preparation method of oxo-pyridine compound and key intermediate | 成都施贝康生物医药科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116751136-A | Novel preparation method of oxo-pyridine compound and key intermediate | 成都施贝康生物医药科技有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116262736-A | Novel oxo-pyridine compound and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-115645543-A | Maytansinoid derivatives, conjugates thereof, and methods of use | 里珍纳龙药品有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115066417-A | Factor XIa inhibitors | 上海京新生物医药有限公司 | 2022-09-16 | — | — | CN | disclosed |
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
| US-8153809-B2 | Dihydropyridone ureas as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153809-B2 | Dihydropyridone ureas as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2393781-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011027106-A1 | THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE | KING'S COLLEGE LONDON (GB) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011027106-A1 | THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE | KING'S COLLEGE LONDON (GB) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010072599-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | ALDH1A1 128/4885GAA 149/4885HTR4 1413/4885 |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | ALDH1A1 1399/4885GAA 4302/4885HTR4 170/4885 |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | SLC10A1, HNMT, OGFR | ALDH1A1 317/4885GAA 664/4885HTR4 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.